



Genetic Signatures issues first tranche of \$14 million share placement

Sydney, Australia, 12 September 2016: Molecular diagnostics company **Genetic Signatures Limited** (ASX:GSS or the Company) is pleased to announce that further to its ASX Announcement of 2nd September 2016, the Board on Thursday 8 September 2016 confirmed the allotment of Tranche 1 of 10,901,161 new shares to be allotted via an institutional placement at an issue price of \$0.47, effectively raising \$5.1 million.

The Company looks forward to announcing the further approval of the Tranche 2 allotment of 17,906,074 shares to raise a further \$8.8 million and a Shareholder Placement Plan (SPP) to raise a further \$1 million, which will be considered as resolutions at the coming EGM proposed for Thursday 13 October 2016.

Genetic Signatures' Chairman, Dr. Nick Samaras, said "I take this opportunity, on behalf of the board, to welcome our new international and domestic shareholders to the register. I also extend our gratitude to existing shareholders who participated in the placement and to those who will participate in the Share Purchase Plan. The proceeds of this oversubscribed placement will enable Genetic Signatures to accelerate its global commercial expansion."

The share placement will be completed in two tranches:

- The first tranche of the new shares being 10,901,161 shares, raising \$5.1 million, issued on Thursday 8 September under Genetic Signatures' capacity pursuant to ASX Listing Rule 7.1.
- The issue of the second tranche of 17,906,074 new shares, raising \$8.8 million, is conditional upon shareholder approval at the forthcoming EGM on 13 October 2016.

Share Purchase Plan

- In conjunction with the share placement, Genetic Signatures will also conduct a Share Purchase Plan (SPP), issuing a further 2,127,659 shares at \$0.47 to raise a further \$1 million and offered to eligible shareholders in Australia and New Zealand.
- Under the SPP, holders of existing shares in Genetic Signatures on the register as at 7.00pm (Sydney time) on the record date of Thursday 1 September 2016, eligible shareholders will be invited to subscribe for up to \$15,000 of new fully paid ordinary shares in Genetic Signatures. The SPP will be capped at \$1 million and participation in the SPP will be optional. Further information in relation to the SPP, including SPP terms and conditions, will be

outlined in a separate SPP Booklet. Approval of the issue of the SPP Booklet will be considered as a resolution at the EGM on 13 October 2016.

The shares to be issued under both tranches and the SPP are fully paid ordinary shares and will rank equally with existing shares on Genetic Signatures from their issue.

For further information, see our website (www.geneticsignatures.com) or contact the following:

Company	Media and Investor Relations
John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580	Peter Taylor Investor Relations Peter@nwrcommunications.com.au T: +61 412 036 231

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3Base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the **EasyScreen™** brand. Genetic Signatures' proprietary MDx **3Base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.